The Experts below are selected from a list of 507 Experts worldwide ranked by ideXlab platform

Dominic Sauvageau - One of the best experts on this subject based on the ideXlab platform.

  • Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler
    Pharmaceutical Research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Zaritza Petrova, Dominic Sauvageau
    Abstract:

    Purpose To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Methods Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log_10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis , were used to quantify phage titer . Results Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log_10(pfu/mL). Active phage delivery rate was significantly greater ( p  

  • anti tuberculosis bacteriophage d29 delivery with a vibrating mesh nebulizer jet nebulizer and Soft Mist Inhaler
    Pharmaceutical Research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Zaritza O Petrova, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Dominic Sauvageau
    Abstract:

    To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis, were used to quantify phage titer. Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log10(pfu/mL). Active phage delivery rate was significantly greater (p < 0.01) for the vibrating mesh nebulizer (3.3x108 ± 0.8x108 pfu/min) than for the jet nebulizer (5.4x104 ± 1.3x104 pfu/min). The Soft Mist Inhaler delivered 4.6x106 ± 2.0x106 pfu per 11.6 ± 1.6 μL ex-actuator dose. Delivering active phage requires a prudent choice of inhalation device. The jet nebulizer was not a good choice for aerosolizing phage D29 under the tested conditions, due to substantial titer reduction likely occurring during droplet production. The vibrating mesh nebulizer is recommended for animal inhalation studies requiring large amounts of D29 aerosol, whereas the Soft Mist Inhaler may be useful for self-administration of D29 aerosol.

  • Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler.
    Pharmaceutical research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Zaritza O Petrova, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Dominic Sauvageau
    Abstract:

    To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis, were used to quantify phage titer. Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log10(pfu/mL). Active phage delivery rate was significantly greater (p 

Nicholas B Carrigy - One of the best experts on this subject based on the ideXlab platform.

  • Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler
    Pharmaceutical Research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Zaritza Petrova, Dominic Sauvageau
    Abstract:

    Purpose To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Methods Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log_10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis , were used to quantify phage titer . Results Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log_10(pfu/mL). Active phage delivery rate was significantly greater ( p  

  • anti tuberculosis bacteriophage d29 delivery with a vibrating mesh nebulizer jet nebulizer and Soft Mist Inhaler
    Pharmaceutical Research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Zaritza O Petrova, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Dominic Sauvageau
    Abstract:

    To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis, were used to quantify phage titer. Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log10(pfu/mL). Active phage delivery rate was significantly greater (p < 0.01) for the vibrating mesh nebulizer (3.3x108 ± 0.8x108 pfu/min) than for the jet nebulizer (5.4x104 ± 1.3x104 pfu/min). The Soft Mist Inhaler delivered 4.6x106 ± 2.0x106 pfu per 11.6 ± 1.6 μL ex-actuator dose. Delivering active phage requires a prudent choice of inhalation device. The jet nebulizer was not a good choice for aerosolizing phage D29 under the tested conditions, due to substantial titer reduction likely occurring during droplet production. The vibrating mesh nebulizer is recommended for animal inhalation studies requiring large amounts of D29 aerosol, whereas the Soft Mist Inhaler may be useful for self-administration of D29 aerosol.

  • Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler.
    Pharmaceutical research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Zaritza O Petrova, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Dominic Sauvageau
    Abstract:

    To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis, were used to quantify phage titer. Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log10(pfu/mL). Active phage delivery rate was significantly greater (p 

Maria Gabriella Matera - One of the best experts on this subject based on the ideXlab platform.

  • Tiotropium formulations and safety: a network meta-analysis:
    Therapeutic advances in drug safety, 2016
    Co-Authors: Mario Cazzola, Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera
    Abstract:

    Tiotropium is now delivered via two different Inhaler devices: the original Handihaler 18 μg once daily, which uses a powder formulation; and the newer Respimat Soft Mist Inhaler (SMI) 5 μg once daily. It has been questioned whether the two devices can be assumed to have the same safety profile, although the TIOSPIR trial showed that tiotropium when administered via Respimat SMI 5 μg is not less safe than Handihaler 18 μg. Therefore, we have carried out a safety evaluation of tiotropium Handihaler 18 µg versus tiotropium Respimat SMI 5 µg and 2.5 µg, via systematic review and network meta-analysis of the currently available clinical evidence. The results of our meta-analysis with an extremely large number of patients analysed demonstrate that the safety profile of tiotropium HandiHaler is generally superior to that of tiotropium Respimat SMI, although no statistical difference was detected between these two devices. However, the SUCRA analysis favoured tiotropium Respimat SMI with regards to serious adverse events (AEs). We do not believe that using Respimat SMI rather that HandiHaler exposes patients to higher risks of real AEs. Rather, we believe that there may be a different cardiovascular (CV) response to muscarinic receptors blockage in individual patients. Therefore, it will be essential to make all possible efforts to proactively identify patients at increased risk of CV AEs when treated with tiotropium or another antimuscarinic drug.

  • differential pharmacology and clinical utility of long acting bronchodilators in copd focus on olodaterol
    Therapeutics and Clinical Risk Management, 2015
    Co-Authors: Maria Gabriella Matera, Mario Cazzola
    Abstract:

    Olodaterol (BI 1744 CL) is a novel, once-daily long-acting β2-agonist (LABA) designed with the aim of improving β2-adrenoreceptor selectivity and intrinsic activity. Phase III pivotal trials have documented that olodaterol Respimat Soft Mist Inhaler 5 μg induces fast onset of bronchodilation, comparable with formoterol at day 1. Moreover, significant lung function improvements have been documented up to 48 weeks in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). Olodaterol was generally well tolerated and had an acceptable cardiovascular and respiratory adverse event profile. Regrettably, the clinical development of olodaterol is however still too partial to draw any firm conclusions on the positioning of this ultra-LABA as monotherapy in the management of COPD. Waiting for further data on the impact of olodaterol on different patient-reported outcomes, which however are widely available for indacaterol, and mainly for a head-to-head comparison between these two ultra-LABAs and between olodaterol long-acting antimuscarinic antagonists other than tiotropium, we believe it is correct to follow the clinical indications of indacaterol also for olodaterol. In any case, the parallel bronchodilating modes of action of olodaterol and tiotropium make them an attractive combination in COPD. The results from the ongoing large TOviTO Phase III trial program have documented the efficacy and safety of olodaterol/tiotropium fixed-dose combination as maintenance therapy in patients with moderate to very severe COPD. In particular, olodaterol/tiotropium fixed-dose combination provides a convincing alternative for patients remaining symptomatic with olodaterol monotherapy.

  • olodaterol tiotropium bromide for the treatment of chronic obstructive pulmonary disease
    Expert Review of Clinical Pharmacology, 2015
    Co-Authors: Mario Cazzola, Paola Rogliani, Maria Gabriella Matera
    Abstract:

    A solid scientific rationale and an increasing body of clinical evidence for combining a β2-agonist with an antimuscarinic agent in COPD fully support the opinion that patients not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action. Tiotropium is an established choice for the management of patients with stable COPD, and olodaterol is a new effective and safe once-daily long-acting β2-agonist. The parallel bronchodilating modes of action of olodaterol and tiotropium make them an attractive combination in COPD. The large ongoing TOviTO Phase III trial program is documenting the efficacy and safety of olodaterol/tiotropium fixed dose combination delivered via the Respimat Soft Mist Inhaler as maintenance therapy in patients with moderate to very severe COPD. However, we must still know whether this fixed-dose combination will affect exacerbations and hospitalizations, and ultimately death, and also the precise estimates of its relative cardiovascular...

  • Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease
    Expert Review of Clinical Pharmacology, 2015
    Co-Authors: Mario Cazzola, Paola Rogliani, Maria Gabriella Matera
    Abstract:

    A solid scientific rationale and an increasing body of clinical evidence for combining a β2-agonist with an antimuscarinic agent in COPD fully support the opinion that patients not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action. Tiotropium is an established choice for the management of patients with stable COPD, and olodaterol is a new effective and safe once-daily long-acting β2-agonist. The parallel bronchodilating modes of action of olodaterol and tiotropium make them an attractive combination in COPD. The large ongoing TOviTO Phase III trial program is documenting the efficacy and safety of olodaterol/tiotropium fixed dose combination delivered via the Respimat Soft Mist Inhaler as maintenance therapy in patients with moderate to very severe COPD. However, we must still know whether this fixed-dose combination will affect exacerbations and hospitalizations, and ultimately death, and also the precise estimates of its relative cardiovascular...

  • Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease
    Expert review of clinical pharmacology, 2015
    Co-Authors: Mario Cazzola, Paola Rogliani, Josuel Ora, Maria Gabriella Matera
    Abstract:

    A solid scientific rationale and an increasing body of clinical evidence for combining a β2-agonist with an antimuscarinic agent in COPD fully support the opinion that patients not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action. Tiotropium is an established choice for the management of patients with stable COPD, and olodaterol is a new effective and safe once-daily long-acting β2-agonist. The parallel bronchodilating modes of action of olodaterol and tiotropium make them an attractive combination in COPD. The large ongoing TOviTO Phase III trial program is documenting the efficacy and safety of olodaterol/tiotropium fixed dose combination delivered via the Respimat Soft Mist Inhaler as maintenance therapy in patients with moderate to very severe COPD. However, we must still know whether this fixed-dose combination will affect exacerbations and hospitalizations, and ultimately death, and also the precise estimates of its relative cardiovascular safety.

Warwick J Britton - One of the best experts on this subject based on the ideXlab platform.

  • Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler
    Pharmaceutical Research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Zaritza Petrova, Dominic Sauvageau
    Abstract:

    Purpose To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Methods Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log_10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis , were used to quantify phage titer . Results Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log_10(pfu/mL). Active phage delivery rate was significantly greater ( p  

  • anti tuberculosis bacteriophage d29 delivery with a vibrating mesh nebulizer jet nebulizer and Soft Mist Inhaler
    Pharmaceutical Research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Zaritza O Petrova, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Dominic Sauvageau
    Abstract:

    To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis, were used to quantify phage titer. Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log10(pfu/mL). Active phage delivery rate was significantly greater (p < 0.01) for the vibrating mesh nebulizer (3.3x108 ± 0.8x108 pfu/min) than for the jet nebulizer (5.4x104 ± 1.3x104 pfu/min). The Soft Mist Inhaler delivered 4.6x106 ± 2.0x106 pfu per 11.6 ± 1.6 μL ex-actuator dose. Delivering active phage requires a prudent choice of inhalation device. The jet nebulizer was not a good choice for aerosolizing phage D29 under the tested conditions, due to substantial titer reduction likely occurring during droplet production. The vibrating mesh nebulizer is recommended for animal inhalation studies requiring large amounts of D29 aerosol, whereas the Soft Mist Inhaler may be useful for self-administration of D29 aerosol.

  • Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler.
    Pharmaceutical research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Zaritza O Petrova, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Dominic Sauvageau
    Abstract:

    To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis, were used to quantify phage titer. Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log10(pfu/mL). Active phage delivery rate was significantly greater (p 

Rachel Yoon Kyung Chang - One of the best experts on this subject based on the ideXlab platform.

  • Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler
    Pharmaceutical Research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Zaritza Petrova, Dominic Sauvageau
    Abstract:

    Purpose To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Methods Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log_10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis , were used to quantify phage titer . Results Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log_10(pfu/mL). Active phage delivery rate was significantly greater ( p  

  • anti tuberculosis bacteriophage d29 delivery with a vibrating mesh nebulizer jet nebulizer and Soft Mist Inhaler
    Pharmaceutical Research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Zaritza O Petrova, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Dominic Sauvageau
    Abstract:

    To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis, were used to quantify phage titer. Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log10(pfu/mL). Active phage delivery rate was significantly greater (p < 0.01) for the vibrating mesh nebulizer (3.3x108 ± 0.8x108 pfu/min) than for the jet nebulizer (5.4x104 ± 1.3x104 pfu/min). The Soft Mist Inhaler delivered 4.6x106 ± 2.0x106 pfu per 11.6 ± 1.6 μL ex-actuator dose. Delivering active phage requires a prudent choice of inhalation device. The jet nebulizer was not a good choice for aerosolizing phage D29 under the tested conditions, due to substantial titer reduction likely occurring during droplet production. The vibrating mesh nebulizer is recommended for animal inhalation studies requiring large amounts of D29 aerosol, whereas the Soft Mist Inhaler may be useful for self-administration of D29 aerosol.

  • Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler.
    Pharmaceutical research, 2017
    Co-Authors: Nicholas B Carrigy, Rachel Yoon Kyung Chang, Sharon S Y Leung, Melissa Harrison, Zaritza O Petrova, Welkin H Pope, Graham F Hatfull, Warwick J Britton, Hakkim Chan, Dominic Sauvageau
    Abstract:

    To compare titer reduction and delivery rate of active anti-tuberculosis bacteriophage (phage) D29 with three inhalation devices. Phage D29 lysate was amplified to a titer of 11.8 ± 0.3 log10(pfu/mL) and diluted 1:100 in isotonic saline. Filters captured the aerosolized saline D29 preparation emitted from three types of inhalation devices: 1) vibrating mesh nebulizer; 2) jet nebulizer; 3) Soft Mist Inhaler. Full-plate plaque assays, performed in triplicate at multiple dilution levels with the surrogate host Mycobacterium smegmatis, were used to quantify phage titer. Respective titer reductions for the vibrating mesh nebulizer, jet nebulizer, and Soft Mist Inhaler were 0.4 ± 0.1, 3.7 ± 0.1, and 0.6 ± 0.3 log10(pfu/mL). Active phage delivery rate was significantly greater (p